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Antibody deficiencies are the most frequent primary immunodeficiencies (PIDs). The majority of patients with antibody deficiencies are diagnosed in early adulthood. Common variable immunodeficiency, selective immunoglobulin (Ig) A deficiency, and IgG subclass deficiency are characterized by a quantitative Ig deficiency and variably impaired responses to vaccines in general and to polysaccharide antigens in particular [1] . These PIDs are generally revealed by recurrent and/or severe bacterial infections (most of which are upper respiratory tract infections [URTIs]), pneumonia, and systemic infections by encapsulated bacteria such as Streptococcus pneumoniae, group A Streptococcus, and Haemophilus influenzae type b [1] .
Specific polysaccharide antibody deficiency (SPAD) is defined by an isolated, impaired antibody response to polysaccharide antigens in the presence of normal serum IgG, IgA, and IgM levels, normal IgG subclass levels, and normal T-cell subpopulations [1, 2] . An impaired antibody response to polysaccharide antigens is usually assessed after immunization with the 23-valent pneumococcal polysaccharide vaccine (PPV23). Antibody responses to protein vaccines (tetanus or diphtheria toxins) and conjugate vaccines are normal in patients with SPAD [1] [2] [3] . SPAD is most frequently reported in children with recurrent URTIs and/or pneumonia. Here, we report on 11 cases of SPAD diagnosed in adulthood following the occurrence of severe bacterial infections.
METHODS
The study was performed in the Department of Clinical Immunology at Lille University Medical Center, France, between January 2013 and January 2016. Patients diagnosed with SPAD after severe bacterial infections were identified in the active case file. Demographic characteristics, medical histories, clinical characteristics, the results of immunologic assessments, and the final diagnosis were recorded. Severe bacterial infection was defined as the occurrence of at least 1 acute severe infection that required hospitalization and/or a chronic bacterial infection that led to chronic lung disease.
The response to pneumococcal capsular polysaccharide (PnPS) was tested in the immunomonitoring facility at Cochin University Medical Center (Paris, France) using the thirdgeneration World Health Organization enzyme-linked immunosorbent assay (the reference serotype-specific assay), as previously described [4] . Titers of antibody against 7 capsular serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) were assessed before and 4 to 8 weeks after the administration of PPV23. The results were interpreted according to the guidelines issued in 2012 by the American Academy of Allergy, Asthma & Immunology (AAAAI) Working Group [3] . Briefly, a participant was considered to have an impaired response for a single serotype if the post-immunization antibody titer was below 1.3 µg/mL (considered to be protective) and/or did not achieve a 4-fold increase (relative to the pre-immunization value). A 2-fold increase was acceptable if the initial titer was already above 1.3 µg/mL. All immunological tests and immunizations were performed at least 3 months after the last infectious event. None of the participants had undergone recent or concomitant treatment with steroids, immunosuppressants, or other medications capable of altering vaccine responses. SPAD was diagnosed if an impaired antibody response was observed for 3 or more of the 7 tested serotypes and if complement deficiencies, serum IgG, IgA, and IgM deficiencies, and IgG subclass deficiencies had been ruled out. Patients were classified as having a severe, moderate, or mild SPAD phenotype, as previously described. "Memory SPAD" (ie, loss of response within 6 months) was not considered in the presents study [1, 2] .
RESULTS
Eleven adult SPAD patients were included in the study ( (Table 1) and Supplementary Tables  1 and 2. SPAD was revealed by an isolated, invasive infection with encapsulated bacteria in 6 patients (patients 1-6). Four of the 6 patients presented with meningococcal infections: bacteremia in 1 case (serotype C for patient 1), meningitis in 2 cases (serotype Y for patient 2 and serotype B for patient 3), and purpura fulminans in the remaining case (serotype C for patient 4). Patient 5 presented with septic shock due to H. influenzae type b, with a pericardial effusion and acute cardiac tamponade. Patient 6 presented with pneumococcal meningitis and partial seizures related to encephalitis. All patients were admitted to an intensive care unit (ICU). None had any significant comorbidities (except for trisomy 21 in patient 5).
The first severe infections in patient 7 (prompting referral to our department) were meningitis (due to H. influenzae type b) and bilateral pneumococcal pneumonia. The patient also experienced recurrent bacterial sinusitis (requiring antibiotic treatment about twice a year).
In patients 8 to 10, SPAD was revealed by recurrent severe pneumonia with bacteremia, hypoxemia, pleurisy, and/or severe sepsis. This condition required repeated hospitalizations, sometimes in the ICU. Patients 9 and 10 had Sjögren's syndrome. Patient 9 also had severe rheumatoid arthritis (RA) but was not treated with immunosuppressants or corticosteroids because of the recurrent severe infections. Only patient 9 was a smoker. Last, patient 11 developed lobar pneumonia, bronchiectasis, and functional lung impairment in a context of recurrent URTIs and bronchopulmonary infections since childhood. By reference to the classic definition of SPAD, all other immunological parameters (complement levels, IgG, IgA, IgM, and IgG subclass levels, and antibody responses to protein antigens and/or conjugate vaccines) were normal, except in patient 9 who displayed hypergammaglobulinemia related to RA and Sjögren's syndrome. However, a low B-cell count was found in 2 patients, and a small proportion of switched memory B-cells was found in 6 patients (Supplementary Table 2) .
After diagnosis, all SPAD patients received comprehensive information on warning signs (such as fever, cough, headaches, and dyspnea) that should prompt them to consult their primary care physician and/or attend hospital in possible cases of severe infection or when antibiotic treatment fails to resolve symptoms.
Patients 1-6 (who presented with isolate invasive bacterial infections) received conjugate vaccines against S. pneumoniae (1-2 years after PPV23 to avoid hyporesponsiveness), H. influenzae type b, and meningococcal serotypes B, A, C, Y, and W135.
Patients 7-11 (with recurrent severe infections) received intravenous or subcutaneous Ig replacement therapy. The infections resolved fully and had not recurred in any of these patients after a median (range) follow-up period of 17 months (6;35).
DISCUSSION
Here, we describe 11 cases of SPAD diagnosed in adulthood following a severe infection with encapsulated bacteria. SPAD (for which effective prophylactic treatments are available) is rarely reported in adulthood and/or in patients with recurrent, benign infections (Supplementary Table 3) .
Antibody primary disorders are usually revealed by recurrent and/or severe infections with encapsulated bacteria. The current guidelines recommend that adults be screened for PIDs if they experience 2 or more severe bacterial infections [5] . In a previous work, we found that PIDs are surprisingly prevalent (19%) in young adults who present with a first invasive infection with encapsulated bacteria [6] .
The lack of an antibody response following immunization with a polysaccharide antigen has been described in various PIDs in which patients are exposed to recurrent and/or severe URTIs and lung infections and, more generally, to encapsulated bacterial infections [3] . The antipolysaccharide response is usually assessed by immunization with a pneumococcal polysaccharide vaccine. All of our patients were diagnosed in accordance with the 2012 AAAAI guidelines on the use and interpretation of diagnostic vaccination [3] . All previous series of SPAD cases diagnosed according to the AAAAI guidelines were related to children and/or in adults presenting with recurrent URTIs (Supplementary Table 3 ). Our series differs in that the cases of SPAD were revealed in adulthood by severe bacterial infections (including meningococcal infections). Humoral immunity is involved in the control of Neisseria meningitidis infections [7] , as suggested by the effectiveness of vaccination. Last, meningococcal infections have been reported in other antibody deficiencies [6, 8] .
It is noteworthy that children aged <2 years, splenectomized patients, and asplenic patients are unable to respond to PnPS immunization and are susceptible to infection by encapsulated bacteria. The lack of anti-PnPS immunization is thought to be due to the immaturity and/or absence of marginal zone B cells [9, 10] . Although the exact mechanism of SPAD has yet to be determined, a small proportion of switched memory B cells observed in 6 of our 11 patients is a further indication of impaired humoral immunity [11] .
As SPAD patients are particularly susceptible to encapsulated bacteria, long-term antibiotic treatment, the administration of conjugate vaccines, and Ig replacement therapy must all be considered as prophylactic measures for preventing the recurrence of infection [1, 2] . In our case series (and despite differences in the length of follow-up), Ig replacement in patients 7-11 seemed to effectively prevent the recurrence of infection. This is noteworthy because prior to Ig replacement therapy, the patients' bacterial infections were severe and required frequent hospitalization (sometimes in the ICU). Second, recurrent infections may be responsible for the acquisition of antibiotic resistance or impaired lung function, as observed in patient 11.
SPAD patients not on Ig replacement therapy received conjugated polysaccharide vaccines. The risk of infection by these encapsulated bacteria is explained to the patient and his/her primary care physician, so that an appropriate antibiotic course will be prescribed for any bacterial infections (eg, URTIs, respiratory symptoms, unexplained fever) and the patient will be referred to the hospital if he/she fails to improve after 24 to 48 hours of treatment.
Larger series and longer follow-up periods are warranted in order to better understand the consequences of mild/moderate/severe phenotypes, B-cell subset abnormalities, and not receiving Ig replacement therapy after a single, severe infection.
In conclusion, SPAD is a primary antibody deficiency that should be immediately considered in adults who develop unexplained, severe bacterial infections (ie, without waiting for recurrence). All physicians who deal with this type of infection should be aware of SPAD. Patient education, the administration of conjugate vaccines, and Ig replacement therapy may all contribute to prophylaxis in SPAD patients.
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